Lilly Alimta patent extended to 2022

Share this article:
Lilly Alimta patent extended to 2022
Lilly Alimta patent extended to 2022

Eli Lilly has added six more years to the patent of its Alimta cancer drug. A lower court decided in favor of the Indianapolis, IN, drugmaker Monday. The decision means the medication, which brought in $2.7 billion in global sales last year and is indicated for nonsquamous non-small cell lung cancer, will not have to face generic competition until 2022.

Bernstein analyst Tim Anderson wrote in his Monday analysis that the win amounts to about three dollars per share, or around 5% of the company's current stock price, but the decision does not change his firm's valuation of Lilly, because its financial models assumed a court would vote in Lilly's favor.

A worst-case scenario could have put Alimta in the generic-eligible bin in 2017. Anderson expects the decision will be appealed, so Monday's news does not mean the patent fights are over.

The company is also fighting for patent extensions in other countries, including Germany and the United Kingdom.

Alimta's US sales totaled $1.2 billion last year, an 8% bump from 2012, due to both higher prices and demand.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...